Neurocrine Biosciences (NBIX) Share-based Compensation (2010 - 2026)

Neurocrine Biosciences' Share-based Compensation history runs 17 years deep, the most recent figure standing at $55.7 million for Q1 2026.

• Quarterly Share-based Compensation rose 5.49% year-over-year to $55.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 98.58% YoY) and the FY2024 annual result came in at $195.5 million, down 2.64% from the prior year.
• Share-based Compensation was $55.7 million for Q1 2026 at Neurocrine Biosciences, up from -$105.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $129.6 million in Q3 2022 and bottomed at -$129.6 million in Q4 2022.
• A 5-year average of $28.2 million and a median of $46.2 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 464.04% — and 2023, when it soared 285.14%.
• Neurocrine Biosciences' Share-based Compensation stood at -$129.6 million in 2022, then surged by 134.41% to $44.6 million in 2023, then soared by 48.88% to $66.4 million in 2024, then sank by 259.04% to -$105.6 million in 2025, then soared by 152.75% to $55.7 million in 2026.
• Business Quant data shows NBIX's Share-based Compensation at $55.7 million in Q1 2026, -$105.6 million in Q3 2025, and $52.8 million in Q2 2025.